



News Release

Illumina Announces Certified Service Provider Program for Sequencing and Names First Participating Organizations

SAN DIEGO--(BUSINESS WIRE)--Jan. 9, 2009--Illumina, Inc. (NASDAQ:ILMN) announced today that it has introduced the Illumina CPro™ Program for Sequencing. This new extension to the program allows organizations with the Illumina Genome Analyzer to become certified in order to provide a range of sequencing-based genetic analysis services. The Illumina CPro Program is the only program of its kind to offer a collaborative partnership that includes co-marketing benefits with a certification process designed to help ensure delivery of the highest data quality available for genetic analysis applications. Illumina has established high performance standards and CPro certifications for each of the Company's array-based assay technologies including GoldenGate^(R) Genotyping, Infinium^(R) Whole-Genome Genotyping, and Whole-Genome Expression. The Illumina CPro Program is modular so that participants can elect to be certified for any or all of the assays or platforms.

Illumina worked closely with the National Center for Genome Resources (NCGR) in Santa Fe, New Mexico and Fasteris SA in Geneva, Switzerland, to validate processes for the CPro Sequencing Program. Thanks to their collaborative efforts, both organizations have completed the certification and assisted in the development of the rigorous standards for the certification, annual audit, and best practices guidelines that will enable other providers to achieve the same quality standards.

The Illumina CPro Sequencing Program has already drawn several world-class service providers in North America, Europe and Asia in its premier stages. GATC Biotech in Europe is already in progress on the sequencing certification. Beijing Genomics Institute (BGI) at Shenzhen in China and Expression Analysis (EA) in the United States are also in early stages of the process.

According to Greg May, Vice President and Director of the Genome Center at NCGR, "The Illumina CPro Program is well aligned with NCGR's credo of collaborative, high data quality, driven bioscience. For NCGR, CPro certification attests to our commitment to provide the highest data quality together with sequence analysis that enables the comprehensive study and understanding of genetic variability in many aspects of human health and crop production."

Laurent Farinelli, co-founder and Chief Executive Officer of Fasteris said, "As the first service provider to order an Illumina Genome Analyzer, being a pilot partner for the CPro Sequencing Program was a natural extension of our commitment to and experience with the technology." Dr. Farinelli added, "We are very pleased to be affiliated with a global program of this nature that emphasizes a commitment to quality, collaboration, and world-class service, principles that are of utmost important to Fasteris as well."

Tristan Orpin, Illumina's Senior Vice President of Commercial Operations stated, "We are pleased to extend our Certified Service Provider Program to include next-generation sequencing on the Genome Analyzer. The rapid adoption of the platform and the subsequent publication stream has created tremendous demand for this extension of CPro. We anticipate end user demand for CPros in the sequencing program to grow rapidly as a result, and are very excited to have such esteemed partners from around the globe in the program."

To find out more about NCGR, Fasteris, GATC, BGI, or Expression Analysis, please visit their respective websites at www.ncgr.org, www.fasteris.com, www.gatc-biotech.com, <http://sz.genomics.org.cn/?lang=en> and www.expressionanalysis.com.

Illumina is currently certifying additional CPro Providers in North America, Europe and Asia. For more information about the CPro Program or to view the most recent list of Illumina certified service providers, visit www.illumina.com/CPro.



About Illumina CPro

Illumina CPro is a collaborative service provider partnership dedicated to ensuring the delivery of the highest-quality data available for genetic analysis applications. Illumina CPros undergo a rigorous two-phase certification process that include minimum data generation, data certification and on-site audit of the facility and processes. Illumina is currently certifying additional CPro Providers in North America, Europe and Asia. For more information about the CPro Program or to view the most recent list of Illumina certified service providers, visit www.illumina.com/CPro.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are Illumina's ability (i) to develop and commercialize further our BeadArray(TM), VeraCode(R), and Solexa(R) technologies and to deploy new sequencing, gene expression, and genotyping products and applications for our technology platforms, (ii) to manufacture robust instrumentation and reagents technology, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.

CONTACT: Illumina, Inc.

Media:

Maurissa Bornstein, Public Relations Manager, 858-332-4055

mbornstein@illumina.com

or

Investors:

Peter J. Fromen, Sr. Director, Investor Relations, 858-202-4507

pfromen@illumina.com

Source: Illumina, Inc.